Pacira Urges Stockholders to Back Board Nominees Amidst Proxy Battle with DOMA
Summary
Pacira BioSciences sent a letter to stockholders, urging them to vote for its board nominees and against those proposed by activist investor DOMA Perpetual, ahead of the June 9th Annual Meeting.
Key Events
-
Ongoing Proxy Battle
Pacira issued a letter to stockholders as part of its active proxy contest with activist investor DOMA Perpetual Capital Management, ahead of the 2026 Annual Meeting.
-
Support for Current Nominees
The company is urging shareholders to vote 'FOR' its three highly qualified director nominees (Christopher Christie, Samit Hirawat, MD, and Thomas Wiggans) on the BLUE proxy card.
-
Opposition to Activist Nominees
Pacira argues that DOMA's director candidates are 'underqualified' and lack relevant industry and governance expertise, warning their election could lead to 'value destruction'.
-
Defense of Strategic Plan
Pacira reiterated its commitment to its '5x30 strategy' for sustainable growth, contrasting it with DOMA's 'unclear plan' which Pacira claims includes cutting costs, discontinuing pipeline development, replacing the CEO, and pursuing an 'immediate sale process'.
Analysis
This filing is a critical communication from Pacira's management to shareholders in an ongoing, high-stakes proxy battle. The company is actively campaigning to retain its current board and strategic direction against activist investor DOMA Perpetual, who seeks to replace the CEO and potentially pursue a sale of the company. The outcome of the June 9th Annual Meeting will directly determine the future leadership and strategic path of Pacira, making this a pivotal moment for the company's governance and long-term value.
At the time of this filing, PCRX was trading at $22.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $898.4M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.